Skip to content

Psychological Intervention for Relapse Prevention in First Episode Schizophrenia

Psychological Intervention for Relapse Prevention in First Episode Schizophrenia

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00161408
Enrollment
106
Registered
2005-09-12
Start date
2000-12-31
Completion date
2005-09-30
Last updated
2005-09-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenic Disorders

Keywords

schizophrenia, first episode, cognitive behavioural therapy, psychoeducation

Brief summary

The study is a randomized clinical trial investigating the efficacy of a comprehensive psychological intervention for the treatment of first episode schizophrenia

Detailed description

Patients suffering from their first episode of schizophrenic disorders are randomly allocated to either a short information centered psychoeducation (ICP) of 8 sessions or a cognitive behavioral treatment (CBT). CBT includes 8 sessions of psychoeducation, 8 sessions of computer based cognitive training, 8 sessions with relatives and 20 sessions of focusing on stress management, relapse prevention and coping with persistent symptoms. The primary endpoint is relapse at the one and two year follow up.

Interventions

BEHAVIORALcognitive behavioural therapy
BEHAVIORALpsychoeducation

Sponsors

University Hospital Tuebingen
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
No

Inclusion criteria

* diagnosis of schizophrenic disorder according to ICD 10: F20 * first episode * age between 18 and 55 * willingness to give informed consent also to a double blind pharmacological treatment study

Exclusion criteria

* residence outside of the catchment area * insufficient knowledge of the German language * substance abuse or addiction as primary clinical problem * serious physical illness * organic brain disease * pregnancy * contraindications to neuroleptic treatment

Design outcomes

Primary

MeasureTime frame
relapse

Secondary

MeasureTime frame
quantitative measures of symptoms
social functioning
cognitive functioning
quality of life

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026